New HCV articles at HIVandHepatitis.com

[Guest guest]

Hepatitis C - Top New Articles

Hepatitis C Patients May Have Increased Risk of Stroke

SUMMARY› People with chronic hepatitis C virus (HCV) infection appear to have a

higher likelihood of dying from strokes than uninfected individuals, according

to research reported in the December 2010 issue of Stroke. Over 17 years of

follow-up, nearly 3% of HCV seropositive people died due to cerebrovascular

events, compared with 1% of HCV negative people; furthermore, the risk of stroke

death rose with increasing HCV viral load.

Anadys Starts Phase 2b Study of HCV Polymerase Inhibitor ANA598

SUMMARY› Anadys Pharmaceuticals announced this week that it has begun treating

the first participants in a Phase 2b clinical trial of its investigational

hepatitis C virus (HCV) polymerase inhibitor ANA598. The new drug will be tested

in combination with pegylated interferon plus ribavirin in both previously

untreated patients and people who did not achieve sustained response to prior

therapy.

HCV Main Section

[Guest guest]

Hepatitis C - Top New Articles

Hepatitis C Patients May Have Increased Risk of Stroke

SUMMARY› People with chronic hepatitis C virus (HCV) infection appear to have a

higher likelihood of dying from strokes than uninfected individuals, according

to research reported in the December 2010 issue of Stroke. Over 17 years of

follow-up, nearly 3% of HCV seropositive people died due to cerebrovascular

events, compared with 1% of HCV negative people; furthermore, the risk of stroke

death rose with increasing HCV viral load.

Anadys Starts Phase 2b Study of HCV Polymerase Inhibitor ANA598

SUMMARY› Anadys Pharmaceuticals announced this week that it has begun treating

the first participants in a Phase 2b clinical trial of its investigational

hepatitis C virus (HCV) polymerase inhibitor ANA598. The new drug will be tested

in combination with pegylated interferon plus ribavirin in both previously

untreated patients and people who did not achieve sustained response to prior

therapy.

HCV Main Section

[Guest guest]

Hepatitis C - Top New Articles

Hepatitis C Patients May Have Increased Risk of Stroke

SUMMARY› People with chronic hepatitis C virus (HCV) infection appear to have a

higher likelihood of dying from strokes than uninfected individuals, according

to research reported in the December 2010 issue of Stroke. Over 17 years of

follow-up, nearly 3% of HCV seropositive people died due to cerebrovascular

events, compared with 1% of HCV negative people; furthermore, the risk of stroke

death rose with increasing HCV viral load.

Anadys Starts Phase 2b Study of HCV Polymerase Inhibitor ANA598

SUMMARY› Anadys Pharmaceuticals announced this week that it has begun treating

the first participants in a Phase 2b clinical trial of its investigational

hepatitis C virus (HCV) polymerase inhibitor ANA598. The new drug will be tested

in combination with pegylated interferon plus ribavirin in both previously

untreated patients and people who did not achieve sustained response to prior

therapy.

HCV Main Section

[Guest guest]

Hepatitis C - Top New Articles

Hepatitis C Patients May Have Increased Risk of Stroke

SUMMARY› People with chronic hepatitis C virus (HCV) infection appear to have a

higher likelihood of dying from strokes than uninfected individuals, according

to research reported in the December 2010 issue of Stroke. Over 17 years of

follow-up, nearly 3% of HCV seropositive people died due to cerebrovascular

events, compared with 1% of HCV negative people; furthermore, the risk of stroke

death rose with increasing HCV viral load.

Anadys Starts Phase 2b Study of HCV Polymerase Inhibitor ANA598

SUMMARY› Anadys Pharmaceuticals announced this week that it has begun treating

the first participants in a Phase 2b clinical trial of its investigational

hepatitis C virus (HCV) polymerase inhibitor ANA598. The new drug will be tested

in combination with pegylated interferon plus ribavirin in both previously

untreated patients and people who did not achieve sustained response to prior

therapy.

HCV Main Section